NCT00503347View on ClinicalTrials.gov

Bavituximab Repeat-Dose Trial in Patients Co-Infected With Chronic Hepatitis C Virus and Human Immunodeficiency Virus

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

July 31, 2007

Primary Completion Date

March 31, 2011

Study Completion Date

June 30, 2011

Conditions
Hepatitis C VirusHiv Infections
Interventions
DRUG

bavituximab

The study drug is a sterile solution administered intravenously weekly for 8 weeks. Each cohort is given 0.3, 1, 3, or 6 mg/kg of bavituximab.

Trial Locations (6)

21287

Johns Hopkins University, Center for Viral Hepatitis, Baltimore

30308

AIDS Research Consortium of Atlanta, Atlanta

75204

Southwest Infectious Disease Associates, Dallas

90036

Impact Clinical Research, Los Angeles

92663

Orange Coast Medical Center, Newport Beach

07102

Saint Michael's Medical Center, Newark

Sponsors
All Listed Sponsors
lead

Peregrine Pharmaceuticals

INDUSTRY